| Literature DB >> 30451874 |
Neil de Kock1, Santosh R Acharya1, S J Kumari A Ubhayasekera2, Jonas Bergquist3.
Abstract
Ultra-performance supercritical fluid chromatography-tandem mass spectrometry (UPSFC-MS/MS) is an alternative method for steroid analysis. Continuous development of analytical methodologies for steroid profiling is of major importance in the clinical environment to provide useful and more comprehensive data. The aim of this study was to identify and quantify a large number of endogenous steroids from the four major classes (estrogens, androgens, progestogens and corticosteroids) simultaneously within a short analytical time. This novel UPSFC-MS/MS method with electrospray in positive ionisation (ESI+) mode is robust, selective and present sufficiently high sensitivity to profile nineteen steroids in 50 µL human plasma. Under optimised conditions, nineteen different steroids were separated with high efficiency in the multiple reaction monitoring (MRM) mode. The linearity of the method was good with correlation coefficients (R2) in the range of 0.9983-0.9999 and with calibration range from 0.05-500 ng/mL in human plasma. The intraday and interday precision of the method, as RSD, was less than 15%. The accuracy of the nineteen analytes varied between 80 to 116%. Finally, the novel method was successfully applied for the determination of nineteen steroids within 5 minutes providing the possibility to use it for research as well as routine healthcare practice.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30451874 PMCID: PMC6242962 DOI: 10.1038/s41598-018-35007-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Steroid hormone biosynthesis pathway with some steroid metabolites in the human body. The four steroid classes are progestogens (yellow), corticosteroids (green), androgens (blue) and estrogens (pink).
Figure 2Typical chromatogram of representative steroids obtained in a single injection of spiked human plasma extract after derivatisation.
Figure 3Chemical reaction of a steroid with methoxyamine (e.g. pregnenolone).
Mass spectrometric parameters for the identification and quantification of the methoxime derivatives of steroids.
| Class of analytes | Compound | Derivative | Corresponding internal standard | Tra (min) | Precursor ion ( | Product ions ( | Collision energy (eV) (1/2/3)c | |
|---|---|---|---|---|---|---|---|---|
| Estrogens | Estrone | E1-MO | d4-E1-MO | 2.28 | 300.1 | 157.0/253.2 | 25/15 | 0.004 |
| Androgens | Dehydroepiandrosterone | DHEA-MO | d2-AN-MO | 2.35 | 318.3 | 110.2/253.2/286.2 | 25/17/18 | 0.004 |
| Androsterone | AN-MO | d2-AN-MO | 2.28 | 320.3 | 255.1/288.2 | 18/18 | 0.004 | |
| Etiocholanolone | ECN-MO | d2-AN-MO | 2.36 | 320.1 | 255.1/288.2 | 18/18 | 0.004 | |
| Androstenedione | AE-diMO | d9-P-diMO | 1.17/1.47 | 345.3 | 260.2/283.2 | 27/26 | 0.019 | |
| Testosterone | T-MO | 13C3-T-MO | 2.25/2.47 | 318.1 | 126.1/138.0 | 29/30 | 0.004 | |
| Dihydrotestosterone | DHT-MO | 13C3-T-MO | 2.13/2.28 | 320.2 | 128.3/140.2 | 29/30 | 0.004 | |
| Progestogens | Pregnenolone | Preg-MO | 13C2-d2-Preg-MO | 2.20 | 346.2 | 100.1/300.1 | 23/26 | 0.004 |
| 17α-Hydroxypregnenolone | 17OHPreg-MO | 13C2-d2-Preg-MO | 2.81 | 362.3 | 344.1 | 5 | 0.033 | |
| Progesterone | P-diMO | d9-P-diMO | 0.90/1.12 | 373.1 | 286.2/327.2 | 28/28 | 0.032 | |
| 17α-Hydroxyprogesterone | 17OHP-diMO | d8-17OHP-diMO | 1.86/1.93 | 389.1 | 228.1/268.1/286.2 | 34/25/25 | 0.004 | |
| Pregnanolone | PONE-MO | 13C2-d2-Preg-MO | 2.24 | 348.1 | 100.0 | 29 | 0.004 | |
| Allopregnanolone | Allo-MO | d5-Allo-MO | 2.12 | 348.2 | 100.0 | 29 | 0.003 | |
| Corticoids | Cortisone | E-diMO | d4-F-diMO | 2.73/2.80 | 419.2 | 300.1/316.1/357.1 | 26/30/29 | 0.004 |
| Cortisol | F-diMO | d4-F-diMO | 3.18/3.53 | 421.2 | 284.1/359.2 | 28/27 | 0.033 | |
| Corticosterone | B-diMO | d8-B-diMO | 2.65/3.07 | 405.1 | 343.1 | 28 | 0.004 | |
| 11-Deoxycortisol | S-diMO | d4-F-diMO | 2.54/2.69 | 405.2 | 286.2/343.2 | 25/25 | 0.004 | |
| 11-Deoxycorticosterone | DOC-diMO | d8-B-diMO | 1.79/2.03 | 389.1 | 126.0/138.0/327.2 | 40/40/28 | 0.004 | |
| Aldosterone | A-diMO | d4-F-diMO | 3.15/3.35 | 419.2 | 357.1 | 29 | 0.033 | |
| Internal standards | d4-estrone | d4-E1-MO | — | 2.28 | 304.2 | 159.0/257.0 | 25/15 | 0.004 |
| d2-Androsterone | d2-AN-MO | — | 2.28 | 322.3 | 257.1/290.21 | 18/18 | 0.004 | |
| 13C3-Testosterone | 13C3-T-MO | — | 2.25/2.47 | 321.3 | 129.2/141.1 | 29/30 | 0.004 | |
| 13C2-d2-Pregnenolone | 13C2-d2-Preg-MO | — | 2.19 | 350.3 | 304.3/104.3 | 21/27 | 0.004 | |
| d5-Allopregnanolone | d5-Allo-MO | — | 2.13 | 353.2 | 105.0 | 29 | 0.003 | |
| d9-Progesterone | d9-P-diMO | — | 0.91/1.12 | 382.3 | 292.2/333.3 | 28/28 | 0.032 | |
| d8-17α-Hydroxyprogesterone | d8-17OHP-diMO | — | 1.86/1.93 | 397.2 | 129.0/273.1/291.1 | 25/25/25 | 0.004 | |
| d4-Cortisol | d4-F-diMO | — | 3.18/3.53 | 425.2 | 288.0/363.0 | 28/29 | 0.033 | |
| d8-Corticosterone | d8-B-diMO | — | 2.65/3.08 | 413.3 | 349.3 | 29 | 0.004 |
Tr: retention time; Dt: dwell time. aRetention time for one or two eluting peaks (from isomeric forms) per compound is reported. bNumber of product ions generated. cCollision energy applied for generating each of the product ions.
Method validation parameters.
| No. | Compound | R2 | Linear range (ng/mL) | LOQ (ng/mL) | Low concentrationa | Medium concentrationa | High concentrationa | Absolute recovery (%) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accuracy (Bias) | Precision (CV%) | Accuracy (Bias) | Precision (CV%) | Accuracy (Bias) | Precision (CV%) | ||||||
| 1 | E1 | 0.9993 | 0.05–30 | 0.05 | −0.1 | 2.6 | 3.5 | 9.9 | 2.9 | 7.3 | 97.7 |
| 2 | DHEA | 0.9998 | 0.1–30 | 0.10 | 0.1 | 11.4 | -2.7 | 14.8 | 4.8 | 4.3 | 95.8 |
| 3 | AN | 0.9999 | 0.05–30 | 0.05 | 8.3 | 4.2 | 5.0 | 7.6 | 8.0 | 0.5 | 94.7 |
| 4 | ECN | 0.9996 | 0.5–30 | 0.50 | 2.6 | 2.1 | 1.4 | 7.0 | 3.1 | 4.7 | 96.1 |
| 5 | AE | 0.9999 | 0.05–30 | 0.05 | 2.4 | 2.5 | 9.0 | 3.7 | 4.2 | 0.7 | 96.8 |
| 6 | T | 0.9998 | 0.05–30 | 0.05 | 5.6 | 6.1 | 15.6 | 10.2 | 12.2 | 12.2 | 87.1 |
| 7 | DHT | 0.9994 | 0.05–30 | 0.05 | 7.1 | 5.2 | 5.0 | 6.9 | 2.1 | 9.2 | 90.0 |
| 8 | Preg | 0.9986 | 0.1–30 | 0.10 | 2.9 | 3.1 | 11.8 | 3.6 | 0.3 | 4.3 | 94.4 |
| 19 | 17OHPreg | 0.9985 | 0.5–30 | 0.5 | 10.1 | 4.3 | 3.1 | 1.7 | 3.5 | 6.1 | 88.3 |
| 10 | P | 0.9999 | 0.05–30 | 0.05 | 15.9 | 0.9 | 5.3 | 1.9 | 13.7 | 0.8 | 89.1 |
| 11 | 17OHP | 0.9999 | 0.25–30 | 0.25 | 13.1 | 3.5 | 3.7 | 3.8 | 0.1 | 4.7 | 81.9 |
| 12 | PONE | 0.9995 | 0.05–30 | 0.05 | 2.4 | 1.7 | 17.5 | 4.8 | 21.6 | 9.5 | 91.3 |
| 13 | Allo | 0.9980 | 0.05–30 | 0.05 | 2.2 | 2.4 | 5.3 | 4.8 | 2.3 | 5.1 | 95.8 |
| 14 | E | 0.9999 | 0.05–500 | 0.05 | 9.2 | 2.6 | 18.8 | 1.7 | 9.3 | 2.8 | 102.8 |
| 15 | F | 0.9992 | 0.05–500 | 0.05 | 16.3 | 3.0 | 18.6 | 1.2 | 18.9 | 1.3 | 104.1 |
| 16 | B | 0.9991 | 0.05–500 | 0.05 | 11.0 | 2.4 | 20.1 | 3.7 | 12.7 | 2.5 | 102.3 |
| 17 | S | 0.9992 | 0.05–500 | 0.05 | 7.9 | 8.7 | 13.1 | 2.3 | 7.8 | 2.3 | 95.7 |
| 18 | DOC | 0.9983 | 0.05–250 | 0.05 | 9.3 | 6.4 | 8.0 | 5.4 | 8.9 | 7.1 | 82.2 |
| 19 | A | 0.9998 | 1–500 | 1.00 | 13.8 | 15.1 | 10.7 | 4.0 | 8.0 | 5.0 | 107.2 |
R2, correlation coefficient; LOQ, limit of quantification; CV%, coefficient of variance; E1, estrone; DHEA, dehydroepiandrosterone; AN, androsterone; ECN, etiocholanolone; AE, androstenedione; T, testosterone; DHT, dihydrotestosterone; Preg, pregnenolone; 17OHPreg, 17α-hydroxypregnenolone; P, progesterone; 17OHP, 17α-hydroxyprogesterone; PONE, pregnanolone; Allo, allopregnanolone; E, cortisone; F, cortisol; B, corticosterone; S, 11-deoxycortisol; DOC, 11-deoxycorticosterone; A, aldosterone. aThe low, medium and high concentrations for compounds 1–13 are 0.25, 2.5 and 20 ng/mL, respectively. The low, medium and high concentrations for compounds 14–19 are 2.5, 20 and 250 ng/mL, respectively.